Applicability of phase I trial results in the design of phase II and III biological response modifier trials.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000592:standards*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D012107:Research Design
D000970:Antineoplastic Agents; D001688:Biological Products